Zevra Therapeutics, Inc. announced the appointment of Alicia Secor to its Board of Directors.
The company also revealed the retirement of Wendy Dixon, PhD, from the Board.
Alicia Secor brings over thirty years of experience in the life sciences industry to her new role at Zevra.
Appointment of Alicia Secor
Alicia Secor joins Zevra's Board of Directors, adding significant leadership experience in rare diseases.
Retirement of Wendy Dixon, PhD
Wendy Dixon, PhD, retires from the Board after providing strategic counsel during her tenure at Zevra.
Alicia Secor's Background
Ms. Secor previously held leadership roles at Atalanta Therapeutics, Juniper Pharmaceuticals, and Genzyme, bringing a wealth of industry experience to Zevra.
- Alicia Secor's appointment strengthens Zevra's Board with her extensive experience in the life sciences sector, particularly in rare diseases.
- The retirement of Wendy Dixon marks a transition in Zevra's Board composition, creating an opportunity for new perspectives and insights.
The addition of Alicia Secor and the retirement of Wendy Dixon mark significant developments for Zevra Therapeutics, underscoring the company's commitment to strategic leadership changes in advancing therapies for rare diseases.